epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2015-14-2-73-78epidemiology-41Research ArticleВАКЦИНОПРОФИЛАКТИКАVACCINAL PREVENTIONПолиомиелит сегодня: состояние Глобальной программы ликвидации и современная стратегия ВОЗ по иммунизацииPolio Today: State of the Global Eradication Program and Modern Strategy of WHO on ImmunizationИвановаО. Е.IvanovaO. E.poliom@aha.ruФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова»; ФГБНУ «Институт полиомиелита и вирусных энцефалитов имени М.П. Чумакова»РоссияFederal State Unitary Enterprise on Manufacture of Bacterial and Viral Preparations of M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides; Federal State Budgetary Scientific Institution «M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides» of the Russian Academy of SciencesRussian Federation2015200420151427378Copyright © Иванова О.Е., 20152015Иванова О.Е.Ivanova O.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/41

В обзоре приведены данные о современном состоянии Глобальной программы ВОЗ по ликвидации полиомиелита. Успех ее выполнения в значительной мере зависит от решения проблем, связанных с продолжающимся использованием трехвалентной оральной полиовирусной вакцины (ОПВ) -вакциноассоциированный паралитический полиомиелит (ВАПП) и вакцинородственные полиовирусы (ВРПВ). Приведена информация о стратегии иммунизации против полиомиелита, предложенной ВОЗ в «Стратегическом плане ликвидации полиомиелита и осуществления завершающего этапа в 2013 - 2018 гг.».

The review presents data on the current stature of the Global Polio Eradication Initiative of the WHO. The success of its implementation mainly depends on the solutions of the problems associated with continuing use of trivalent oral poliovirus vaccine (OPV): vaccine- associated paralytic poliomyelitis (VAPP) and vaccine-derived polioviruses (VDPV). The information about the polio immunization strategy proposed by WHO in «Polio Eradication and Endgame Strategic Plan 2013 - 2018» is presented.

полиомиелиторальная полиовирусная вакцина (ОПВ)вакцинородственные полиовирусы (ВРПВ)вакциноассоциированный паралитический полиомиелит (ВАПП)poliomyelitisoral poliovirus vaccine (OPV)vaccine-associated paralytic poliomyelitis (VAPP)vaccine-derived polioviruses (VDPV)ReferencesSutter R.W., Kew O.M., Cochi S.L., Aylward R.B. Poliovirus vaccine-live. In: Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines, 6th ed. Philadelphia; PA: Elsevier- Saunders; 2013: 598 - 645.Sutter R.W., Kew O.M., Cochi S.L., Aylward R.B. Poliovirus vaccine-live. In: Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines, 6th ed. Philadelphia; PA: Elsevier- Saunders; 2013: 598 – 645.Resolution of the 41st World Health Assembly WHA 41.28. Global Eradication of poliomyelitis by the year 2000. WHO, Geneva; 1988. Доступно на: http:// www.who.int/ihr/polioresolution4128en.pdfResolution of the 41st World Health Assembly WHA 41.28. Global Eradication of poliomyelitis by the year 2000. WHO, Geneva; 1988. Available at: http://www.who.int/ihr/polioresolution4128en.pdfVidor E., Plotkin S.A. Poliovirus vaccine - inactivated. In: Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines, 6th ed. Philadelphia, PA: Elsevier-Saunders; 2013: 573 - 597.Vidor E., Plotkin S.A., Poliovirus vaccine – inactivated. In: Plotkin S.A., Orenstein W.A., Offit P.A., eds. Vaccines, 6th ed. Philadelphia, PA: Elsevier-Saunders; 2013: 573 – 597.WHO. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec. 2014; 89 (9): 73 - 92.WHO. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec. 2014; 89 (9): 73−– 92.WHO. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 - conclusions and recommendations. Wkly Epidemiol Rec. 2014; 89 (21): 221 - 236.WHO. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol. Rec. 2014; 89 (21): 221−– 236.Okayasu H., Sutter R.W., Czerkinsky C., Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine. 2011; 29 (46): 8205 - 8214.Okayasu H., Sutter R.W., Czerkinsky C., Ogra P.L. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine. 2011; 29 (46): 8205 – 8214.Hird T.R., Grassly N. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012; 8 (4). Доступно на: http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002599Hird T.R., Grassly N. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012; 8 (4). Available at: http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002599Anis E., Kopel E., Singer S.R., Kaliner E., Moerman L., Moran-Gilad J. et al. Insidious reintroduction of wild poliovirus into Israel. 2013. Euro Surv. 2013; 18 (38). Доступно на: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20586Anis E., Kopel E., Singer S.R., Kaliner E., Moerman L., Moran-Gilad J., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surv. 2013; 18 (38). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20586Лашкевич В.А. История создания в 1959 г. живой вакцины из аттенуированных штаммов А. Сэбина и идея искоренения полиомиелита. Вопр. вирусол. 2013; 1: 4 - 10.Lashkevich V.A. History of development of the live poliomyelitis vaccine from Sabin attenuated strains in 1959 and idea of poliomyelitis eradication. Vopr. Virusol. 2013; 1: 4 −– 10 (in Russian).Приказ МЗ России от 21.03.2014 года № 125н «Об утверждении Национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям». Доступно на: http://base.garant.ru/70647158/Order of the Ministry of Health of the Russian Federation of 21.03.2014 № 125n «On approval of the National Immunization Schedule and Calendar of preventive vaccination on epidemic indications». Available at: http://base.garant.ru/70647158/ (in Russian).WHO. Transmission of wild poliovirus type 2 - apparent global interruption. Wkly Epidemiol Rec. 2001; 76 (13): 95 - 97.WHO. Transmission of wild poliovirus type 2 – apparent global interruption. Wkly Epidemiol Rec. 2001; 76 (13): 95 – 97.Kew O.M., Cochi S.L., Jafari H.S., Wassilak S.G., Mast E.E., Diop O.M. et al. Possible eradication of wild poliovirus type 3 - worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014; 63 (45): 1031 - 1033.Kew O.M., Cochi S.L., Jafari H.S., Wassilak S.G., Mast E.E., Diop O.M. et al. Possible eradication of wild poliovirus type 3 – worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014; 63 (45): 1031 – 1033.WHO. Report of the Independent Monitoring Board of the Global Polio Eradication Initiative, November 2012. Доступно на: http://www.polioeradication. org/Portals/0/Document/Aboutus/Governance/IMB/7IMBMeeting/7IMB_Report_EN.pdfWHO. Report of the Independent Monitoring Board of the Global Polio Eradication Initiative, November 2012. Available at: http://www.polioeradication.org/Portals/0/Document/Aboutus/Governance/IMB/7IMBMeeting/7IMB_Report_EN.pdfCDC. Certification of poliomyelitis eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43 (39): 720 -722.CDC. Certification of poliomyelitis eradication – the Americas, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43 (39): 720 – 722.CDC. Certification of poliomyelitis eradication - the Western Pacific region, October 2000. MMWR Morb Mortal Wkly Rep. 2001; 50 (1): 1 - 3.CDC. Certification of poliomyelitis eradication – the Western Pacific region, October 2000. MMWR Morb Mortal Wkly Rep. 2001; 50 (1): 1– 3.CDC. Certification of poliomyelitis eradication - European Region, June 2002. MMWR Morb Mortal Wkly Rep. 2002; 51 (26): 572 - 574.CDC. Certification of poliomyelitis eradication – European Region, June 2002. MMWR Morb Mortal Wkly Rep. 2002; 51 (26): 572 – 574.Bahl S., Kumar R., Menabde N., Thapa A., McFarland J., Swezy V. et al. Polio-free certification and lessons learned - South-East Asia. MMWR Morb Mortal Wkly Rep. 2014; 63 (42): 941 - 946.Bahl S., Kumar R., Menabde N., Thapa A., McFarland J., Swezy V. et al. Polio-free certification and lessons learned – South-East Asia. MMWR Morb Mortal Wkly Rep. 2014; 63 (42): 941 – 946.WHO. Risk assessment: frequency and burden of VAPP cVDPV and iVDPV. Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis: Geneva, 13 14 November 2002. Geneva: WHO; 2002.WHO. Risk assessment: frequency and burden of VAPP, cVDPV and iVDPV. Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis: Geneva, 13 − 14 November 2002. Geneva: WHO; 2002.Platt L.R., Estivariz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 2014; 210 (S1): 380 - 389.Platt L.R., Estivariz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 2014; 210 (1): 380 – 389.Иванова О.Е., Еремеева Т.П., Лещинская Е.В., Короткова Е.А., Яковенко М.Л., Чернявская О.П. и др. Паралитический полиомиелит в Российской Федерации в 1998 - 2005 гг. ЖМЭИ. 2007; 5: 37 - 44.Ivanova O.E., Eremeeva T.P., Leshchinskaya E.V., Korotkova E.A., Yakovenko M.L., Chernyavskaya O.P. et al. Paralytic poliomyelitis in Russian Federation in 1998 − 2005. Zh. Microbiol. Epidemiol. Immunobiol. 2007; 5: 37 – 44 (in Russian).Prevots D.R., Sutter R.W., Strebel P.M., Weibel R.E., Cochi S.L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch Pediatr Adolesc Med. 1994; 148 (5): 479 - 485.Prevots D.R., Sutter R.W., Strebel P.M., Weibel R.E., Cochi S.L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch. Pediatr. Adolesc. Med. 1994; 148 (5): 479 – 485.Alexander L.N., Seward J.F., Santibanzes T.A., Pallansch M.A., Kew O.M., Prevots D.R. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA; 2004; 292 (14): 1696 - 1701.Alexander L.N., Seward J.F., Santibanzes T.A., Pallansch M.A., Kew O.M., Prevots D.R. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004; 292 (14): 1696−– 1701.WHO. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010; 85 (23): 213 - 228.WHO. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol. Rec. 2010; 85 (23): 213 − 228.Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew O.M. et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Inf. Dis. 1992; 14 (2): 568 - 579.Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew OM. et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Inf. Dis. 1992; 14 (2): 568−– 579.Приказ МЗ СР РФ № 673 от 30.10.2007 года «О внесении изменений в Приказ Минздрава России от 27 июня 2001 г. № 229 «О национальном календаре профилактических прививок и календаре профилактических прививок по эпидемическим показаниям». Доступно на: http://www.garant.ru/ products/ipo/prime/doc/4085698/Order of the Ministry of Health of the Russian Federation № 673 of 30.10.2007 «On Amendments to the Order of Ministry of Health of Russia on June 27, 2001 № 229 «On the national calendar of preventive vaccinations and calendar of preventive vaccination on epidemic indications». Available at: http://www.garant.ru/products/ipo/prime/doc/4085698/ (in Russian).Иванова О.Е., Еремеева Т.П., Яковенко М.Л., Гмыль А.П., Шакарян А.К., Байкова О.Ю. и др. Вакциноассоциированный полиомиелит в Российской Федерации и современная стратегия вакцинации. Материалы Международной конференции «Молекулярная эпидемиология актуальных инфекций». Санкт-Петербург, 5 - 7 июня 2013 г. Инфекция и иммунитет. 2013; 3 (2): 97 - 196.Ivanova O.E., Eremeeva T.P., Yakovenko M.L., Gmyl’ A.P., Shakaryan A.K., Baykova O.Yu. et al. Vaccine-associated paralytic poliomyelitis in the Russian Federation and the current vaccination strategies. Materials of the International Conference «Molecular epidemiology of actual infections», Saint-Petersburg, 5−– 7 June 2013. Infection and Immunity. 2013; 3 (2): 97 – 196 (in Russian).Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann. Rev. Microbiol. 2005; 59: 587 - 635.Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005; 59: 587 – 635.Diop U., Burns C., Wassilak S., Kew O. Update on Vaccine-Derived Polioviruses - Worldwide, July 2012 - December 2013. MMWR Morbid Mortal Wkly Rep. 2014; 63 (11): 242 - 248.Diop U., Burns C., Wassilak S., Kew O. Update on Vaccine-Derived Polioviruses – Worldwide, July 2012 ‒ December 2013. MMWR Morbid Mortal Wkly Rep. 2014; 63 (11): 242 – 248.Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P. et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J. Infect Dis. 2011; 203: 898 - 909.Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P. et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J. Infect. Dis. 2011; 203: 898 – 909.Yang C., Naguib T., Yang S., Nasr S., Jorba J., Ahmed N. et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egipt from 1983 1993. J. Virol. 2003; 77 (15): 8366 - 8377.Yang C., Naguib T., Yang S., Nasr S., Jorba J., Ahmed N. et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egipt from 1983 – 1993. J. Virol. 2003; 77 (15): 8366−– 8377.CDC. Circulation of a type 2 vaccine-derived poliovirus - Egipt, 1982 - 1993. MMWR Morbid Mortal Wkly Rep. 2001; 50 (3): 41 - 42.CDC. Circulation of a type 2 vaccine-derived poliovirus – Egipt, 1982-1993. MMWR Morbid Mortal Wkly Rep. 2001; 50 (3): 41 –− 42.CDC. Update on vaccine-derived polioviruses - worldwide, April 2011 - June 2012. MMWR Morbid Mortal Wkly Rep. 2012; 61 (37): 741 - 746.CDC. Update on vaccine-derived polioviruses – worldwide, April 2011 − June 2012. MMWR Morbid Mortal Wkly Rep. 2012; 61 (37): 741 –−746.Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J. Epidemiol. 2010; 172 (11): 1213 - 1229.Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am. J. Epidemiol; 2010; 172 (11): 1213 −– 1229.CDC. Laboratory surveillance for wild and vaccine-derived polioviruses - worldwide, January 2008 June 2009. MMWR Morb Mortal Wkly Rep. 2009; 58 (34): 950 - 954.CDC. Laboratory surveillance for wild and vaccine-derived polioviruses – worldwide, January 2008 ‒ June 2009. MMWR Morb Mortal Wkly Rep; 2009; 58 (34): 950 – 954.DeVries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J. et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 2011; 364 (24): 2316 - 2323.DeVries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J. et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 2011; 364 (24): 2316 – 2323.Sutter R.W., Prevots D.R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 1994; 11: 426 - 438.Sutter R.W., Prevots D.R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 1994; 11: 426−– 438.Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., Sutter R.W. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 2003; 188 (12): 1845 - 1852.Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., Sutter RW. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 2003; 188 (12): 1845−– 1852.Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J. et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull of the WHO. 2004; 82 (1): 3 - 8.Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J. et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull of the WHO. 2004; 82 (1): 3 − 8.Khan A.J., Gebreselassie H., Asturias E.J., Agboatwalla M., Teklehaimanot R., Luby S.P. et al. No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala. Biologicals. 2006; 34 (2): 113 - 116.Khan A.J., Gebreselassie H., Asturias E.J., Agboatwalla M., Teklehaimanot R., Luby S.P. et al. No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala. Biologicals. 2006; 34 (2): 113−– 116.Li L., Ivanova O., Driss N., Tiongco-Recto M., da Silva R., Shahmahmoodi S. et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J. Infect. Dis. 2014; 210 (1): 368 - 372.Li L., Ivanova O., Driss N., Tiongco-Recto M., da Silva R., Shahmahmoodi S. et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J. Infect. Dis. 2014; 210 (1): 368−– 372.Pavlov D.N., van Zyl W.B., van Heerden J., Kruger M., Blignaut L., Grabow W.O. et al. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa. J. Appl. Microbiol. 2006; 101 (6): 1367 - 1379.Pavlov D.N., Van Zyl W.B., van Heerden J., Kruger M., Blignaut L., Grabow W.O. et al. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa. J. Appl. Microbiol. 2006; 101 (6): 1367 – 1379.de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara B.A. et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine; 2012; 30(52): 7561 - 7565.de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara B.A. et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012; 30 (52): 7561 – 7565.Triki H., Barbouche M.R., Bahri O., Bejaoui M., Dellagi K. Community-acquired poliovirus infection in children with primary immunodeficiency in Tunisia. J. Clin. Microbiol. 2003; 41 (3): 1203 - 1211.Triki H., Barbouche M.R., Bahri O., Bejaoui M., Dellagi K. Community-acquired poliovirus infection in children with primary immunodeficiency in Tunisia. J. Clin. Microbiol. 2003; 41 (3): 1203−– 1211.Al-Hello H., Jorba J., Blomqvist S., Raud R., Kew O., Roivainen M. Highly divergent types 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J. Virol. 2013; 87 (23): 13076 - 13080.Al-Hello H., Jorba J., Blomqvist S., Raud R., Kew O., Roivainen M. Highly divergent types 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J. Virol. 2013; 87 (23): 13076−– 13080.WHO. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol. Rec. 2013; 88 (1): 1 - 16.WHO. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol. Rec. 2013; 88 (1): 1−– 16.WHO. Polio Eradication and Endgame Strategic Plan 2013 - 2018. Доступно на: http://www.polioeradication.org/Portals/0/Document/Resources/ StrategyWork/PEESP_EN_A4.pdfWHO. Polio Eradication and Endgame Strategic Plan 2013 – 2018. Available at: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_A4.pdfSutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H. et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010; 376 (9753): 1682 - 1688.Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H. et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010; 376 (9753): 1682 −– 1688.O’Reilly K.M., Durry E., ul Islam O., Ouddus A., Abid N., Mir T.P et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001 - 2011: a retrospective analysis. Lancet. 2012; 380 (9840): 491 - 498.O’Reilly K.M., Durry E., ul Islam O., Ouddus A., Abid N., Mir T.P. et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001 – 2011: a retrospective analysis. Lancet. 2012; 380 (9840): 491 – 498.Cochi S.L., Jafari H.S., Armstrong G.L., Sutter R.W., Linkins R.W., Pallansch M.A. et al. A world without polio. J. Infect. Dis. 2014; 210 (1): 1 - 4.Cochi S.L., Jafari H.S., Armstrong G.L., Sutter R.W., Linkins R.W., Pallansch M.A. et al. A world without polio. J. Infect. Dis. 2014; 210 (1): 1 – 4.Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J Infect. Dis. 2014; 210 (1): 283 - 293.Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J. Infect. Dis. 2014; 210 (1): 283−– 293.McKinlay M., Collett M., Hincks J., Oberste S., Pallansch M., Okayasu H. et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 2014; 210 (S1): 447 - 453.McKinlay M., Collett M., Hincks J., Oberste S., Pallansch M., Okayasu H. et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 2014; 210 (1): 447 –−453.

The authors declare that there are no conflicts of interest present.